Showing results (201-210 of 235) with videos related to

Sort By:
Pageof 24
The Oncologist|September 15, 2017
FDA Approval Summary: Daratumumab for Treatment of Multiple Myeloma After One Prior TherapyVishal Bhatnagar, Nicole J Gormley, Lola Luo, et al.
International Journal of Food Microbiology|March 10, 2009
Campylobacter genotypes from food animals, environmental sources and clinical disease in Scotland 2005/6Samuel K Sheppard, John F Dallas, Marion MacRae, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 9, 2023
Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA PerspectiveAndrea C Baines, Maryam Sarraf Yazdy, Yvette L Kasamon, et al.
The Journal of Urology|July 2, 1998
Influence of finasteride on free and total serum prostate specific antigen levels in men with benign prostatic hyperplasiaJ Pannek, L S Marks, J D Pearson, et al.
Advanced Healthcare Materials|February 3, 2022
Machine-Assisted Discovery of Chondroitinase ABC Complexes toward Sustained Neural RegenerationShashank Kosuri, Carlos H Borca, Heloise Mugnier, et al.
Rheumatology (Oxford, England)|May 6, 2003
Can diagnostic triage by general practitioners or rheumatology nurses improve the positive predictive value of referrals to early arthritis clinics?G J Gormley, W K Steele, A Gilliland, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2022
FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple MyelomaAndrea C Baines, Rachel Ershler, Bindu Kanapuru, et al.
Journal of Clinical Microbiology|November 14, 2008
Campylobacter immunity and coinfection following a large outbreak in a farming communityK J Forbes, F J Gormley, J F Dallas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 25, 2023
FDA Approval Summary: Pirtobrutinib for Relapsed or Refractory Mantle Cell LymphomaDeepti Telaraja, Yvette L Kasamon, Justin S Collazo, et al.
Immunopharmacology|August 11, 2000
C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl alpha-ketoheterocyclesS T Furlong, A S Dutta, M M Coath, et al.
Pageof 24